GoodRx Holdings (GDRX) Liabilities and Shareholders Equity (2019 - 2026)
GoodRx Holdings' Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $1.4 billion for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 1.15% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.3 billion, a 5.8% decrease, with the full-year FY2025 number at $1.4 billion, up 1.15% from a year prior.
- Liabilities and Shareholders Equity hit $1.4 billion in Q4 2025 for GoodRx Holdings, up from $1.3 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for GDRX hit a ceiling of $1.7 billion in Q3 2023 and a floor of $1.3 billion in Q1 2025.
- Historically, Liabilities and Shareholders Equity has averaged $1.5 billion across 5 years, with a median of $1.6 billion in 2022.
- Biggest five-year swings in Liabilities and Shareholders Equity: grew 9.35% in 2021 and later decreased 20.68% in 2024.
- Tracing GDRX's Liabilities and Shareholders Equity over 5 years: stood at $1.6 billion in 2021, then fell by 0.19% to $1.6 billion in 2022, then decreased by 0.99% to $1.6 billion in 2023, then decreased by 12.63% to $1.4 billion in 2024, then grew by 1.15% to $1.4 billion in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for GDRX at $1.4 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.3 billion in Q2 2025.